Company profile: Lucy Therapeutics
1.1 - Company Overview
Company description
- Provider of mitochondrial-based small molecule therapies targeting mitochondrial dysfunction to treat complex diseases with a focus on neurological disorders; diagnostic biomarkers for disease diagnosis and progression monitoring; lead programs in Parkinson's disease and Rett syndrome; and early discovery efforts for undisclosed targets.
Products and services
- Mitochondrial-based Small Molecule Therapies: Engineers mitochondria-targeted products addressing mitochondrial dysfunction in complex diseases with a focus on neurological disorders, acting on mitochondrial proteins to drive therapeutic effects
- Parkinson’s Disease Program: Architects a lead-stage therapeutic program that targets mitochondrial dysfunction in Parkinson’s disease by modulating mitochondrial proteins to address neurodegenerative pathology
- Rett Syndrome Program: Develops an advanced-stage therapeutic program addressing mitochondrial dysfunction in Rett syndrome, engaging mitochondrial protein targets to create treatments for this neurological disorder
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lucy Therapeutics
Abcam
HQ: United Kingdom
Website
- Description: Provider of antibodies, proteins, and kits and reagents for life science research, validated for research use to support scientific studies and facilitate experimental procedures. Helps researchers with breakthroughs in cancer, neurological disorders, infectious diseases, and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abcam company profile →
Nextal Biotech
HQ: United States
Website
- Description: Provider of products designed for experimental crystallization needs, offering plates with grease-free, independent, screwable crystallization supports.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nextal Biotech company profile →
Scireq
HQ: Canada
Website
- Description: Provider of laboratory equipment for preclinical respiratory research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scireq company profile →
Harbour Antibodies
HQ: United States
Website
- Description: Provider of transgenic mouse technology for engineering mice to produce high affinity human antibodies. Established in 2006, leveraging technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands). The company has developed two types of human immunoglobulin gene transgenic mice.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbour Antibodies company profile →
Eleva Biologics
HQ: Germany
Website
- Description: Provider of novel biological therapies developed with pharmaceutical partners, leveraging a unique moss-based production platform to produce biologics such as antibodies, replacement enzymes, and fusion toxins; has advanced drug candidates into clinical phases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleva Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lucy Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lucy Therapeutics
2.2 - Growth funds investing in similar companies to Lucy Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lucy Therapeutics
4.2 - Public trading comparable groups for Lucy Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →